Items Tagged ‘targeted therapy’

September 21st, 2017

Alecensa Appears Superior to Xalkori in ALK positive NSCLC Involving the Brain

By

The results from two separate clinical studies comparing Alecensa® (alectinib) to Xalkori (crizotinib) presented at the European Society for Medical Oncology in Madrid demonstrate that Alecensa®  s superior in treating non small cell lung caner (NSCLC) that has spread to the brain in anaplastic lymphoma kinase (ALK) gene positive NSCLC. Non-squamous NSCLC is the most […]

View full entry

Tags: Alecensa, alectinib, alk, anaplastic lymphoma kinase, brain metastases, crizotinib, gene positive NSCLC, Lung Cancer - Non-Small Cell, News, non small cell lung caner, nsclc, Precision Cancer Medicine


September 5th, 2017

FDA Approves Mylotarg for Treatment of Acute Myeloid Leukemia

By

The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML). The FDA also approved Mylotarg for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who […]

View full entry

Tags: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, AML, CD33 antigen, gemtuzumab ozogamicin, Leukemia, Mylotarg, News, Precision Cancer Medicine, targeted therapy


August 22nd, 2017

The US Food and Drug Administration has approved Besponsa for the Treatment of Refractory B-cell Precursor Acute Lymphoblastic Leukemia

By

Besponsa (Inotuzumab ozogamicin) is a targeted therapy designed to bind to B-cell acute lymphoblastic leukemia (ALL) cancer cells that express the CD22 antigen. Acute lymphoblastic leukemia comprises approximately 25% of cancer diagnoses among children under 15 years old and is the most common childhood cancer in the US1. Effective treatment options for patients with r/r […]

View full entry

Tags: Acute Lymphoblastic Leukemia, all, B-cell, Besponsa, Inotuzumab, Leukemia, News, ozogamicin, targeted therapy


August 2nd, 2017

Pediatric MATCH Trial to Test Targeted Drugs in Childhood Cancers

By

Today investigators at the National Cancer Institute (NCI) and the Children’s Oncology Group (COG) announced the opening of enrollment for a unique precision medicine clinical trial. NCI-COG Pediatric Molecular Analysis for Therapy Choice (Pediatric MATCH) is a nationwide trial to explore whether targeted therapies can be effective for children and adolescents with solid tumors that […]

View full entry

Tags: Brain Cancer, brain tumors, children with solid tumors, histiocytoses, News, non-Hodgkin lymphomas, Non-Hodgkin's Lymphoma, Pediatric MATCH trial, Precision Cancer Medicine, targeted therapy


July 5th, 2017

Genmab Announces Preliminary Cervical Cancer Data from Tisotumab Vedotin Phase I/II Study

By

Data from an ongoing clinical study of tisotumab vedotin in solid tumors has demonstrated activity in the treatment of cervical cancer; 11 of 34 evaluable patients achieved a response; with a median time of treatment of 4.9 months and 7 responders are still ongoing or in follow up for progression. The GEN701 study is ongoing […]

View full entry

Tags: Cervical Cancer, MoAb, News, Precision Cancer Medicine, targeted therapy, Tisotumab Vedotin


June 26th, 2017

FDA grants regular approval to dabrafenib and trametinib combination for metastatic NSCLC with BRAF V600E mutation

By

The U.S. Food and Drug Administration granted regular approvals to Tafinlar® (dabrafenib) and Mekinist® (trametinib) administered in combination for patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. These are the first FDA approvals specifically for treatment of patients with BRAF V600E mutation-positive metastatic NSCLC. The […]

View full entry

Tags: dabrafenib, Lung Cancer, Lung Cancer - Non-Small Cell, mekinist, News, non-small cell lung cancer, precision cancer medicines, tafinlar, targeted therapy, trametinib


June 20th, 2017

Precision Therapy Enasidenib Effective in Treating Acute Myeloid Leukemia

By

According to early clinical trial results published in the journal Blood, some patients with relapsed or treatment-resistant acute myeloid leukemia may achieve remission with an experimental targeted therapy. AML is the most lethal of the blood cancers, which together are the third leading cause of cancer deaths in the U.S.; AML is responsible for more […]

View full entry

Tags: 2016, Acute Myeloid Leukemia, AML, asco, blood cancer, COMFORT 1, Enasidenib, IDH2 gene, jakafi, Leukemia, myelofibrosis, News


June 6th, 2017

Targeted Therapies Show Initial Effectiveness in Subset of Papillary Thyroid Cancer

By

Two immunotherapy drugs currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of melanoma also show promise for treating a rare but aggressive form of papillary thyroid cancer. Up to 44 percent of papillary thyroid cancer patients have a B-raf mutation that can be specifically targeted by existing cancer drugs. The […]

View full entry

Tags: B-raf mutations, mekinist, News, papillary thyroid cancer, precision medicine, tafinlar, targeted therapy, Thyroid Cancer


November 8th, 2016

Personalized Lung Cancer Care & Precision Medicine

By

Targeted and more-individualized treatment for NSCLC becomes a reality. Lung cancers used to be diagnosed solely by a visual microscopic examination of tumor tissue and all patients received the same chemotherapy. Now, doctors are personalizing care by finding the genetic alterations within the cancer that drive its growth and then use medicines that specifically counteract […]

View full entry

Tags: Alcensa, ALK mutation, EGFR, General Lung Cancer, gilotrif, iressa, Lung Cancer, Lung Cancer - Non-Small Cell, Lung Cancer - Small Cell, Necitumumab, News, nsclc


June 7th, 2016

First Targeted Therapy Shows Promise in Small Cell Lung Cancer

By

Small cell lung cancer (SCLC) accounts for approximately 20–25% of all lung cancers. SCLC is an aggressive and fast-growing type of cancer that is very responsive to chemotherapy. However, although initial anticancer responses to chemotherapy may be substantial, long-term survival for patients with SCLC remains poor. Survival in SCLC is no more than 15%, 2 […]

View full entry

Tags: antibody-drug conjugate, DLL3, Lung Cancer, Lung Cancer - Non-Small Cell, News, Recurrent Lung Cancer - Non-Small Cell, Rova-T, Rovalpituzumab tesirine, sclc, small cell lung cancer, targeted therapy


May 30th, 2016

New Breakthrough May Advance Triple Negative Breast Cancer Treatment

By

By Helen Young Scientists at The Scripps Research Institute have developed a new drug candidate that lowers the growth rate of tumor cells in animal models1 in one of the most difficult cancers to battle: triple negative breast cancer. This is the first time that scientists have been able to take a genetic sequence and design […]

View full entry

Tags: Breast Cancer, genetic sequence, microRNA, microRNA-96, News, RNA, Targaprimir-96, targeted therapy, Triple Negative Breast Cancer


May 19th, 2015

Target Therapy Sutent® Promising in Advanced Thyroid Cancer

By

The targeted therapy Sutent® (sunitinib) appears effective in the treatment of patients with advanced differentiated thyroid cancers. The Endocrine Society announced these Phase II trial findings in a press release. Study results were also presented at the Endocrine Society’s 97th annual meeting in San Diego, March 5–8, 2015. Differentiated thyroid cancer is the most common […]

View full entry

Tags: News, sunitinib, Sutent, targeted therapy, Thyroid Cancer